1.Characteristic analysis of HPV infection in 5 152 gynecological patients in some regions of Guangxi
Xiaogang WANG ; Xiaohuan MAO ; Bixiao WEI ; Zhuning MO
International Journal of Laboratory Medicine 2016;(2):218-220
Objective To analyze the characteristics of 5 152 cases HPV genotyping in Guangxi province ,which will be benefit for the control of HPV infection and provid experimental evidence for clinical treatment .Methods Statistically analyze the positive detection rate of all the HPV subtypes ,the differences in the positive rate between people of different genders and ages .Results The total positive rate was 37 .46% (1 930/5 152) .The subtypes with the top seven positive rates were HPV16 (5 .90% ) ,HPV52 (5 .36% ) ,HPV58(4 .04% ) ,HPV6(3 .40% ) ,HPV53(2 .66% ) ,HPV11(2 .43% ) ,HPV18(2 .19% ) ,which were mainly high‐risk subtypes .The total positive rate of male patients was 87 .71% ,while female patients was 34 .45% ,the total positive rate of male pa‐tiets was higher than women .For the positive rate of HPV6 ,HPV11 and HPV58 ,male patients were higher than women ,while for HPV52 female patients was higher than men(P<0 .05) .High‐risk HPV6 ,HPV11 ,HPV42 ,HPV43 infection were characterized by the tendency of younger patients ,the differences were statistically significant(P<0 .05) ,the positive infection rate of patients equal or less than 20 years old(75 .51% ) was higher than other age groups .Conclusion HPV infection rates are very high in some re‐gions of Guangxi ,and attention should be paid to male HPV infection .The subtypes with the top seven positive infection rate are mainly high‐risk subtypes .Low‐risk subtypes such as HPV6 ,11 ,42 ,43 are characterized by the tendency of younger patients .The distribution of HPV infection was affected by region ,gender and age .The investigation of HPV subtypes in Guangxi and do HPV screening in different age groups could help the prevention of cervical cancer and understanding HPV infection outcome .
2.Application of multiplex PCR for the screening of genotyping system for the rare blood groups Fy(a-), s-,k-,Di(b-) and Js(b-).
Wei JIAO ; Li XIE ; Hailan LI ; Jiao LAN ; Zhuning MO ; Ziji YANG ; Fei LIU ; Ruiping XIAO ; Yunlei HE ; Luyi YE ; Ziyan ZHU
Chinese Journal of Medical Genetics 2014;31(2):242-246
OBJECTIVETo screen rare blood groups Fy(a-), s-, k-, Di(b-) and Js(b-) in an ethnic Zhuang population.
METHODSSequence-specific primers were designed based on single nucleotide polymorphism (SNP) sites of blood group antigens Fy(b) and s. A specific multiplex PCR system I was established. Multiplex PCR system II was applied to detect alleles antigens Di(b), k, Js(b)1910 and Js(b) 2019 at the same time. The two systems was were used to screen for rare blood group antigens in 4490 randomly selected healthy donors of Guangxi Zhuang ethnic origin.
RESULTSWe successfully made the multiplex PCR system I. We detected the rare blood group antigens using the two PCR system. There are five Fy(a-), three s(-), two Di(b-) in 4490 Guangxi zhuang random samples. The multiplex PCR system I has achieved good accuracy and stability. With multiplex PCR systems I and II, 4490 samples were screened. Five Fy(a-), three s(-) and two Di(b-) samples were discovered.
CONCLUSIONMultiplex PCR is an effective methods, which can be used for high throughput screening of rare blood groups. The rare blood types of Guangxi Zhuang ethnic origin obtained through the screening can provide valuable information for compatible blood transfusion. Through screening we obtained precious rare blood type materials which can be used to improve the capability of compatible infusion and reduce the transfusion reactions.
Blood Group Antigens ; genetics ; Duffy Blood-Group System ; genetics ; Genotype ; Humans ; Multiplex Polymerase Chain Reaction ; methods ; Receptors, Cell Surface ; genetics
3.The treatment of refractory wounds with apheresis platelet-rich plasma
Ruixian LUO ; Zefeng SHI ; Huiyan LIANG ; Yanping LI ; Guiqiu SHAN ; Zhuning MO
Chinese Journal of Blood Transfusion 2024;37(9):991-997
【Objective】 To explore the model of treatment of refractory wounds by apheresis platelet-rich plasma (PRP), and evaluate its efficacy and safety. 【Methods】 PRP treatment was carried out for 34 patients with refractory wounds who were hospitalized in our hospital from June 2020 to December 2023. The patient′s autologous PRP was collected by the blood composition separator. PRP point-like injection and/or direct application along the edge of the wound, or platelet gel (PG) to cover the wound and fill the sinus were used to treat different types of wounds. The frequency of treatment was once to twice a week, with each course of treatment consisting of 4 to 5 sessions. The efficacy was observed and recorded, and the safety was evaluated. 【Results】 Before PRP collection, the basal platelet, white blood cell and red blood cell counts were (321.85±114.64) ×109/L, (9.52±3.21) ×109/L and (4.34±0.62) ×1012/L, respectively. The counts of platelets, white blood cells and red blood cells in PRP products were (1 438.53±376.89)×109/L, (1.38±1.03)×109/L and (0.03±0.01)×1012/L, respectively. The platelet concentration of PRP products increased by 4.47 times on average, and the sampled bacterial culture was negative. Out of 34 patients treated with PRP, 33 showed improvement in symptoms, while 1 did not respond well due to long-term bedridden and poor compliance. Four patients had mild adverse reactions during PRP collection or treatment, but all were able to complete PRP collection or treatment after standardized treatment. 【Conclusion】 Apheresis PRP products have the advantages of stable quality, safety, reliability and traceability, and can effectively promote the healing of a variety of refractory wounds. Its treatment process is safe and effective, and is worthy of popularization and application.
4.Thromboelastography and routine coagulation tests in the management of coagulation during ECMO therapy: a comparative study
Hao LI ; Sina LI ; Huini HUANG ; Ziji YANG ; Huiqiong XIE ; Ruixian LUO ; Shulin XIANG ; Hailan LI ; Zhuning MO
Chinese Journal of Blood Transfusion 2024;37(6):613-619
【Objective】 To investigate the correlation and consistency between the parameters of thromboelastography(TEG) and routine coagulation tests, and to evaluate the application value of the two methods in heparin anticoagulation monitoring and coagulation function monitoring in patients receiving extracorporeal membrane oxygenation(ECMO) therapy. 【Methods】 A total of 138 patients who recieved ECMO in the Department of Critical Care Medicine of the People′s Hospital of Guangxi Zhuang Autonomous Region from October 2021 to December 2022 were selected. A total of 317 pairs of ordinary TEG and heparinase-modified TEG(hmTEG) parameters measured simultaneously were analyzed for correlation and consistency with activated partial thromboplastin time(APTT), fibrinogen(Fib), and platelet count(Plt), and the parameters tested when ECMO was established and 24 hours after ECMO operation were compared. 【Results】 The correlation coefficient between R values and APTT of hmTEG(r=0.441, P<0.05) was lower than that of ordinary TEG(r=0.547, P<0.05). The parameters α-Angle and K value of ordinary TEG were not correlated with Fib(P>0.05), while as for hmTEG, the correlation was 0.359(P<0.05) and -0.343(P<0.05), respectively. The correlation between MA value of hmTEG and Plt was 0.456(P<0.05), which was much lower than its correlation with Fib(r=0.715, P<0.05). APTT and hmTEG had moderate agreement in judging the anticoagulant effect of UFH(P<0.05). Plt at 24 hours after ECMO was significantly lower than that at establishment of ECMO(P<0.05). Fib, APTT and hmTEG parameters were not significantly different between the two groups(P>0.05). 【Conclusion】 The parameters of hmTEG can better reflect the real level of coagulation factors in patients receiving ECMO. The results of hmTEG and APTT are complementary to assess whether heparin in ECMO patients is overdosed, and hmTEG has unique advantages. Routine coagulation tests and TEG cannot replace each other, and the combination of them can achieve better anticoagulation and coagulation management.